Does the media refer more to HSIC or COO?

In the previous week, Cooper Companies had 7 more articles in the media than Henry Schein. MarketBeat recorded 11 mentions for Cooper Companies and 4 mentions for Henry Schein. Henry Schein's average media sentiment score of 0.64 beat Cooper Companies' score of 0.33 indicating that Henry Schein is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Henry Schein 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cooper Companies 4 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to MMSI or HSIC?

In the previous week, Merit Medical Systems had 1 more articles in the media than Henry Schein. MarketBeat recorded 5 mentions for Merit Medical Systems and 4 mentions for Henry Schein. Merit Medical Systems' average media sentiment score of 1.25 beat Henry Schein's score of 0.64 indicating that Merit Medical Systems is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merit Medical Systems 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Henry Schein 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, HSIC or PODD?

Henry Schein has higher revenue and earnings than Insulet. Henry Schein is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Henry Schein $13.18B 0.75 $398M $3.31 26.11 Insulet $2.71B 4.21 $247.10M $4.30 38.25

Is HSIC or PODD more profitable?

Insulet has a net margin of 10.44% compared to Henry Schein's net margin of 2.95%. Insulet's return on equity of 26.87% beat Henry Schein's return on equity. Company Net Margins Return on Equity Return on Assets Henry Schein 2.95% 15.44% 5.53% Insulet 10.44% 26.87% 12.01%

Does the media refer more to HSIC or PODD?

In the previous week, Insulet had 14 more articles in the media than Henry Schein. MarketBeat recorded 18 mentions for Insulet and 4 mentions for Henry Schein. Henry Schein's average media sentiment score of 0.64 beat Insulet's score of 0.44 indicating that Henry Schein is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Henry Schein 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 4 Very Positive mention(s) 1 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer HSIC or AMN?

In the previous week, Henry Schein had 1 more articles in the media than AMN Healthcare Services. MarketBeat recorded 4 mentions for Henry Schein and 3 mentions for AMN Healthcare Services. AMN Healthcare Services' average media sentiment score of 0.80 beat Henry Schein's score of 0.64 indicating that AMN Healthcare Services is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Henry Schein 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AMN Healthcare Services 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Henry Schein (HSIC) Competitors

$86.43 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$86.43 0.00 (0.00%)

As of 07/2/2026 05:54 PM Eastern

Compare

HSIC vs. COO, IDXX, MMSI, PODD, and AMN

Should you buy Henry Schein stock or one of its competitors? MarketBeat compares Henry Schein with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Henry Schein include Cooper Companies (COO), IDEXX Laboratories (IDXX), Merit Medical Systems (MMSI), Insulet (PODD), and AMN Healthcare Services (AMN). These companies are all part of the "medical" sector.

How does Henry Schein compare to Cooper Companies?

Henry Schein (NASDAQ:HSIC) and Cooper Companies (NASDAQ:COO) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings.

Henry Schein has higher revenue and earnings than Cooper Companies. Henry Schein is trading at a lower price-to-earnings ratio than Cooper Companies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Henry Schein	$13.18B	0.75	$398M	$3.31	26.11
Cooper Companies	$4.09B	3.54	$374.90M	$1.18	62.88

96.6% of Henry Schein shares are held by institutional investors. Comparatively, 24.4% of Cooper Companies shares are held by institutional investors. 0.9% of Henry Schein shares are held by insiders. Comparatively, 2.1% of Cooper Companies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Henry Schein currently has a consensus price target of $87.85, suggesting a potential upside of 1.64%. Cooper Companies has a consensus price target of $81.31, suggesting a potential upside of 9.58%. Given Cooper Companies' higher possible upside, analysts plainly believe Cooper Companies is more favorable than Henry Schein.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Henry Schein	1 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.43
Cooper Companies	3 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.38

Henry Schein has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, Cooper Companies has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

In the previous week, Cooper Companies had 7 more articles in the media than Henry Schein. MarketBeat recorded 11 mentions for Cooper Companies and 4 mentions for Henry Schein. Henry Schein's average media sentiment score of 0.64 beat Cooper Companies' score of 0.33 indicating that Henry Schein is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Henry Schein	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cooper Companies	4 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cooper Companies has a net margin of 5.57% compared to Henry Schein's net margin of 2.95%. Henry Schein's return on equity of 15.44% beat Cooper Companies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Henry Schein	2.95%	15.44%	5.53%
Cooper Companies	5.57%	10.88%	7.27%

Summary

Cooper Companies beats Henry Schein on 9 of the 16 factors compared between the two stocks.

How does Henry Schein compare to IDEXX Laboratories?

IDEXX Laboratories (NASDAQ:IDXX) and Henry Schein (NASDAQ:HSIC) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

IDEXX Laboratories has higher earnings, but lower revenue than Henry Schein. Henry Schein is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.30B	10.22	$1.06B	$13.58	41.08
Henry Schein	$13.18B	0.75	$398M	$3.31	26.11

IDEXX Laboratories presently has a consensus target price of $751.00, indicating a potential upside of 34.64%. Henry Schein has a consensus target price of $87.85, indicating a potential upside of 1.64%. Given IDEXX Laboratories' stronger consensus rating and higher possible upside, equities research analysts clearly believe IDEXX Laboratories is more favorable than Henry Schein.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.64
Henry Schein	1 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.43

IDEXX Laboratories has a beta of 1.55, meaning that its share price is 55% more volatile than the broader market. Comparatively, Henry Schein has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

IDEXX Laboratories has a net margin of 24.63% compared to Henry Schein's net margin of 2.95%. IDEXX Laboratories' return on equity of 70.87% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	24.63%	70.87%	32.56%
Henry Schein	2.95%	15.44%	5.53%

87.8% of IDEXX Laboratories shares are owned by institutional investors. Comparatively, 96.6% of Henry Schein shares are owned by institutional investors. 0.8% of IDEXX Laboratories shares are owned by company insiders. Comparatively, 0.9% of Henry Schein shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Henry Schein had 4 more articles in the media than IDEXX Laboratories. MarketBeat recorded 4 mentions for Henry Schein and 0 mentions for IDEXX Laboratories. Henry Schein's average media sentiment score of 0.64 beat IDEXX Laboratories' score of 0.25 indicating that Henry Schein is being referred to more favorably in the news media.

Company	Overall Sentiment
IDEXX Laboratories	Neutral
Henry Schein	Positive

Summary

IDEXX Laboratories beats Henry Schein on 10 of the 15 factors compared between the two stocks.

How does Henry Schein compare to Merit Medical Systems?

Merit Medical Systems (NASDAQ:MMSI) and Henry Schein (NASDAQ:HSIC) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

Merit Medical Systems has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Henry Schein has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market.

Henry Schein has higher revenue and earnings than Merit Medical Systems. Henry Schein is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merit Medical Systems	$1.52B	2.80	$128.49M	$2.31	30.77
Henry Schein	$13.18B	0.75	$398M	$3.31	26.11

Merit Medical Systems has a net margin of 9.03% compared to Henry Schein's net margin of 2.95%. Henry Schein's return on equity of 15.44% beat Merit Medical Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merit Medical Systems	9.03%	13.54%	7.94%
Henry Schein	2.95%	15.44%	5.53%

99.7% of Merit Medical Systems shares are held by institutional investors. Comparatively, 96.6% of Henry Schein shares are held by institutional investors. 0.7% of Merit Medical Systems shares are held by company insiders. Comparatively, 0.9% of Henry Schein shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Merit Medical Systems presently has a consensus target price of $92.80, indicating a potential upside of 30.54%. Henry Schein has a consensus target price of $87.85, indicating a potential upside of 1.64%. Given Merit Medical Systems' stronger consensus rating and higher possible upside, equities research analysts clearly believe Merit Medical Systems is more favorable than Henry Schein.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merit Medical Systems	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Henry Schein	1 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Merit Medical Systems had 1 more articles in the media than Henry Schein. MarketBeat recorded 5 mentions for Merit Medical Systems and 4 mentions for Henry Schein. Merit Medical Systems' average media sentiment score of 1.25 beat Henry Schein's score of 0.64 indicating that Merit Medical Systems is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merit Medical Systems	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Henry Schein	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Merit Medical Systems beats Henry Schein on 10 of the 16 factors compared between the two stocks.

How does Henry Schein compare to Insulet?

Henry Schein (NASDAQ:HSIC) and Insulet (NASDAQ:PODD) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

Henry Schein has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market. Comparatively, Insulet has a beta of 1.11, indicating that its share price is 11% more volatile than the broader market.

Henry Schein presently has a consensus target price of $87.85, suggesting a potential upside of 1.64%. Insulet has a consensus target price of $238.67, suggesting a potential upside of 45.10%. Given Insulet's stronger consensus rating and higher probable upside, analysts clearly believe Insulet is more favorable than Henry Schein.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Henry Schein	1 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.43
Insulet	2 Sell rating(s)	4 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Insulet had 14 more articles in the media than Henry Schein. MarketBeat recorded 18 mentions for Insulet and 4 mentions for Henry Schein. Henry Schein's average media sentiment score of 0.64 beat Insulet's score of 0.44 indicating that Henry Schein is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Henry Schein	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	4 Very Positive mention(s)	1 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Henry Schein has higher revenue and earnings than Insulet. Henry Schein is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Henry Schein	$13.18B	0.75	$398M	$3.31	26.11
Insulet	$2.71B	4.21	$247.10M	$4.30	38.25

96.6% of Henry Schein shares are held by institutional investors. 0.9% of Henry Schein shares are held by insiders. Comparatively, 0.4% of Insulet shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Insulet has a net margin of 10.44% compared to Henry Schein's net margin of 2.95%. Insulet's return on equity of 26.87% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Henry Schein	2.95%	15.44%	5.53%
Insulet	10.44%	26.87%	12.01%

Summary

Insulet beats Henry Schein on 11 of the 16 factors compared between the two stocks.

How does Henry Schein compare to AMN Healthcare Services?

Henry Schein (NASDAQ:HSIC) and AMN Healthcare Services (NYSE:AMN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

Henry Schein has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.41, indicating that its stock price is 59% less volatile than the broader market.

Henry Schein presently has a consensus target price of $87.85, suggesting a potential upside of 1.64%. AMN Healthcare Services has a consensus target price of $27.00, suggesting a potential downside of 22.16%. Given Henry Schein's stronger consensus rating and higher possible upside, analysts clearly believe Henry Schein is more favorable than AMN Healthcare Services.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Henry Schein	1 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.43
AMN Healthcare Services	2 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.22

Henry Schein has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Henry Schein, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Henry Schein	$13.18B	0.75	$398M	$3.31	26.11
AMN Healthcare Services	$2.73B	0.49	-$95.70M	-$0.87	N/A

96.6% of Henry Schein shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 0.9% of Henry Schein shares are held by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Henry Schein had 1 more articles in the media than AMN Healthcare Services. MarketBeat recorded 4 mentions for Henry Schein and 3 mentions for AMN Healthcare Services. AMN Healthcare Services' average media sentiment score of 0.80 beat Henry Schein's score of 0.64 indicating that AMN Healthcare Services is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Henry Schein	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AMN Healthcare Services	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Henry Schein has a net margin of 2.95% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Henry Schein's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Henry Schein	2.95%	15.44%	5.53%
AMN Healthcare Services	-0.95%	18.01%	5.19%

Summary

Henry Schein beats AMN Healthcare Services on 12 of the 16 factors compared between the two stocks.

Get Henry Schein News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HSIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HSIC vs. The Competition

Export

Metric	Henry Schein	MED/DENTAL Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.85B	$17.82B	$7.18B	$12.47B
Dividend Yield	N/A	1.31%	2.67%	6.51%
P/E Ratio	26.11	19.34	28.02	24.70
Price / Sales	0.75	2.41	534.82	99.70
Price / Cash	11.11	14.43	49.26	57.09
Price / Book	2.61	3.38	10.96	6.46
Net Income	$398M	$534.24M	$3.57B	$337.01M
7 Day Performance	1.74%	0.75%	2.12%	1.69%
1 Month Performance	11.59%	3.67%	5.25%	3.81%
1 Year Performance	15.76%	1.28%	33.29%	23.90%

Henry Schein Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HSIC Henry Schein	3.3222 of 5 stars	$86.43 flat	$87.85 +1.6%	+15.8%	$9.85B	$13.18B	26.11	25,000	Positive News
COO Cooper Companies	2.6177 of 5 stars	$65.42 -0.7%	$81.31 +24.3%	+1.6%	$12.85B	$4.09B	55.44	15,000
IDXX IDEXX Laboratories	3.5517 of 5 stars	$545.73 -2.9%	$751.00 +37.6%	+2.1%	$44.34B	$4.30B	40.19	11,000
MMSI Merit Medical Systems	4.3574 of 5 stars	$66.50 -1.1%	$92.80 +39.5%	-24.0%	$4.01B	$1.54B	28.79	7,500	News Coverage Positive News
PODD Insulet	4.5593 of 5 stars	$138.97 -4.7%	$240.78 +73.3%	-45.4%	$10.10B	$2.71B	32.32	5,400	Trending News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HSIC) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Henry Schein (HSIC) Competitors

HSIC vs. COO, IDXX, MMSI, PODD, and AMN

How does Henry Schein compare to Cooper Companies?

Summary

How does Henry Schein compare to IDEXX Laboratories?

Summary

How does Henry Schein compare to Merit Medical Systems?

Summary

How does Henry Schein compare to Insulet?

Summary

How does Henry Schein compare to AMN Healthcare Services?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSIC vs. The Competition

Henry Schein Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Henry Schein (HSIC) Competitors

HSIC vs. COO, IDXX, MMSI, PODD, and AMN

How does Henry Schein compare to Cooper Companies?

Which has preferable valuation & earnings, HSIC or COO?

Do insiders and institutionals believe in HSIC or COO?

Do analysts rate HSIC or COO?

Which has more volatility & risk, HSIC or COO?

Does the media refer more to HSIC or COO?

Is HSIC or COO more profitable?

Summary

How does Henry Schein compare to IDEXX Laboratories?

Which has preferable valuation & earnings, IDXX or HSIC?

Do analysts rate IDXX or HSIC?

Which has more volatility and risk, IDXX or HSIC?

Is IDXX or HSIC more profitable?

Do insiders & institutionals believe in IDXX or HSIC?

Does the media prefer IDXX or HSIC?

Summary

How does Henry Schein compare to Merit Medical Systems?

Which has more volatility and risk, MMSI or HSIC?

Which has stronger earnings and valuation, MMSI or HSIC?

Is MMSI or HSIC more profitable?

Do insiders & institutionals have more ownership in MMSI or HSIC?

Do analysts recommend MMSI or HSIC?

Does the media refer more to MMSI or HSIC?

Summary

How does Henry Schein compare to Insulet?

Which has more risk & volatility, HSIC or PODD?

Do analysts recommend HSIC or PODD?

Does the media refer more to HSIC or PODD?

Which has higher valuation and earnings, HSIC or PODD?

Do insiders and institutionals hold more shares of HSIC or PODD?

Is HSIC or PODD more profitable?

Summary

How does Henry Schein compare to AMN Healthcare Services?

Which has more volatility and risk, HSIC or AMN?

Do analysts recommend HSIC or AMN?

Which has stronger earnings and valuation, HSIC or AMN?

Do insiders & institutionals hold more shares of HSIC or AMN?

Does the media prefer HSIC or AMN?

Is HSIC or AMN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HSIC vs. The Competition

Henry Schein Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools